Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

About Us

CHANGING LIVES, TOGETHER

Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the cancer continuum.

With a leading portfolio of products for earlier detection and treatment guidance, we help people face the most challenging decisions with confidence.

Our dedication to taking on the impossible fuels everything we do. We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing.

We are Exact Sciences, and we’re changing lives together through earlier detection and smarter answers.

Our Purpose

We strive to change lives through earlier, smarter answers across the cancer journey.

module-dna-icon
Our Promise

We relentlessly pursue life-changing answers in cancer that give people the clarity they need to take action, earlier.

teamwork
Our Principles
  • Earlier Answers
  • Advanced Science & Technology
  • Human Spirit
  • Visionary Collaborations
  • Rooted in Communities
icon-shield